Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNIK | Q9UKE5 | 17/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2367152 | 0.88 | TNIK (0.52) | TNIK | |
| SCHEMBL3394973 | 0.86 | TNIK (0.54) | TNIKALDH1A1POLB | |
| SCHEMBL2367445 | 0.82 | TNIK (0.58) | TNIK | |
| SCHEMBL3394585 | 0.82 | TNIK (0.53) | TNIKPOLB | |
| SCHEMBL3397594 | 0.81 | TNIK (0.53) | TNIK | |
| SCHEMBL13248609 | 0.80 | TNIK (0.47) | TNIKPOLB | |
| SCHEMBL3398208 | 0.80 | TNIK (0.53) | TNIKPOLB | |
| SCHEMBL2367114 | 0.78 | TNIK (0.61) | TNIKALDH1A1POLB | |
| SCHEMBL3394455 | 0.78 | TNIK (0.62) | TNIKPOLB | |
| SCHEMBL3396605 | 0.78 | TNIK (0.61) | TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364149-B1 | TNIK INHIBITOR AND THE USE | NAT CANCER CT (JP) | 2014-05-07 | — | — | EP | disclosed |
| EP-2364149-B1 | TNIK INHIBITOR AND THE USE | NAT CANCER CT (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-08-26 | — | — | US | disclosed |
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-08-26 | — | — | US | disclosed |
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-08-26 | — | — | US | disclosed |
| WO-2010064111-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI (JP) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010064111-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | TNIK, TNNI3K, TNK1 | TNIK 1/4885ALDH1A1 3970/4885POLB 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.